|
Ixico PLC - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Reports results for the six months ended March 31. Revenue increases 23% to £3.9 million from £3.2 million the year before, ‘driven by new contract wins, contract extensions and an increased volume of analyses’. Pretax loss widens to £1.6 million from £889,000. Sales and marketing expenses increase 23% to £1.1 million from GBP£862,000, with total operating expenses increasing 19% to £3.3 million from £2.8 million. Order book totals £18.1 million at March 31, up from £13.1 million one year prior. Company reaffirms guidance of 15% revenue growth for the full year. Chief Executive Officer Bram Goorden says Ixico ‘is now in a more stable and resilient position’ and ‘is well placed to deliver on its ambitions and create sustainable value in the years ahead.’ Current stock price: 8.80 pence, up 30% on Tuesday afternoon in London 12-month change: down 2.3% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
